Does Karen J. Wilson’s Connect Biopharma Form 3 show any recent share purchases or sales?

No purchases or sales are shown. All entries are classified as holdings, and transaction summaries report zero buy and sell transactions. The disclosure focuses on her existing stock option awards and direct Ordinary Share ownership rather than new market activity.

Connect Biopharma director reports option holdings

Connect Biopharma Holdings Ltd director Karen J. Wilson reported her equity holdings in the company.

Accepted by SEC EDGAR 03/16/2026 - 04:43 PM EDT

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Connect Biopharma Holdings Ltd director Karen J. Wilson reported her equity holdings in the company. The filing lists stock options over multiple blocks of Ordinary Shares, including rights to buy 89,220 shares at an exercise price of $8.1600 per share expiring on November 1, 2030, alongside additional options at exercise prices of $4.1200, $1.2700, $1.1800, $0.9600, and $2.5000 with expirations between March 1, 2032 and March 2, 2036. She also directly holds 10,000 Ordinary Shares. Footnotes state that one option grant is fully vested and exercisable, and another will fully vest and become exercisable on March 2, 2027.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider WILSON KAREN J

Role Director

Type	Security	Shares	Price	Value
Holding	Stock Option (Right to Buy)	--	--	--
Holding	Stock Option (Right to Buy)	--	--	--
Holding	Stock Option (Right to Buy)	--	--	--
Holding	Stock Option (Right to Buy)	--	--	--
Holding	Stock Option (Right to Buy)	--	--	--
Holding	Stock Option (Right to Buy)	--	--	--
Holding	Ordinary Shares	--	--	--

Holdings: Stock Option (Right to Buy) — 278,208 contracts (Direct); Ordinary Shares — 10,000 shares (Direct)

Footnotes (2)

F1. The stock option is fully vested and exercisable.
F2. The stock option fully vests and becomes exercisable on March 2, 2027.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Karen J. Wilson report owning in Connect Biopharma (CNTB)?

Karen J. Wilson reports holding several stock option awards and 10,000 Ordinary Shares of Connect Biopharma. The options cover multiple blocks of underlying shares at different exercise prices and expiration dates, reflecting a structured long-term equity compensation position.

How many Connect Biopharma Ordinary Shares does Karen J. Wilson hold directly?

She holds 10,000 Ordinary Shares directly. In addition to this share position, she has multiple stock options that, if exercised, would give her the right to acquire further Ordinary Shares at preset exercise prices before their respective expiration dates.

What stock option positions over Connect Biopharma shares are disclosed for Karen J. Wilson?

The filing lists stock options over blocks of 89,220, 21,269, 21,269, 26,450, 60,000, and 60,000 underlying Ordinary Shares. Exercise prices range from $0.9600 to $8.1600, with expiration dates between November 1, 2030 and March 2, 2036, all held directly.

What do the vesting footnotes in Karen J. Wilson’s Connect Biopharma filing indicate?

One footnote states that a stock option grant is fully vested and exercisable. Another notes a separate stock option will fully vest and become exercisable on March 2, 2027, highlighting both already-available and future exercisable components in her equity awards.

What are the exercise price ranges and expirations of Karen J. Wilson’s Connect Biopharma options?

Her options carry exercise prices of $8.1600, $4.1200, $1.2700, $1.1800, $0.9600, and $2.5000. Expiration dates span from November 1, 2030 through March 2, 2036, illustrating staggered, long-dated grants.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

WILSON KAREN J

(Last)

(First)

(Middle)

3580 CARMEL MOUNTAIN ROAD, SUITE 200

(Street)

SAN DIEGO

92130

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/16/2026

3. Issuer Name and Ticker or Trading Symbol
Connect Biopharma Holdings Ltd [ CNTB ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	10,000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽¹⁾	11/01/2030	Ordinary Shares	89,220	$8.16	D
Stock Option (Right to Buy)	⁽¹⁾	03/01/2032	Ordinary Shares	21,269	$4.12	D
Stock Option (Right to Buy)	⁽¹⁾	03/01/2033	Ordinary Shares	21,269	$1.27	D
Stock Option (Right to Buy)	⁽¹⁾	03/01/2034	Ordinary Shares	26,450	$1.18	D
Stock Option (Right to Buy)	⁽¹⁾	06/24/2035	Ordinary Shares	60,000	$0.96	D
Stock Option (Right to Buy)	⁽²⁾	03/02/2036	Ordinary Shares	60,000	$2.5	D

Explanation of Responses:

1. The stock option is fully vested and exercisable.

2. The stock option fully vests and becomes exercisable on March 2, 2027.

Remarks:

	/s/ Lisa Peraza attorney-in-fact for Karen J Wilson	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR